DeepMed Research

Celltrion Inc

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Established: 1999-01-01

Employees: -

Market Cap: $31.9B

Website: http://www.celltrion.com/

Clinical Trials

A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

Phase 3

Not yet recruiting

Conditions: Refractory or Relapsed Multiple Myeloma

Interventions: Biological: CT-P44(Daratumumab)
Biological: Darzalex Faspro(Daratumumab)

First Posted Date: 2025-05-01

Last Posted Date: 2025-05-04

Lead Sponsor: Celltrion

Target Recruit Count: 486

Registration Number: NCT06952478

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects

Phase 1

Not yet recruiting

Conditions: Healthy Male Subjects

Interventions: Biological: CT-P43

First Posted Date: 2025-04-30

Last Posted Date: 2025-04-30

Lead Sponsor: Celltrion

Target Recruit Count: 160

Registration Number: NCT06951828

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Guro-gu, Korea, Republic of

A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

Phase 3

Recruiting

Conditions: Non Squamous Non Small Cell Lung Cancer

Interventions: Drug: CT-P51
Drug: EU-approved Keytruda

First Posted Date: 2025-04-23

Last Posted Date: 2025-04-23

Lead Sponsor: Celltrion

Target Recruit Count: 606

Registration Number: NCT06939595

Locations: 🇬🇪
ltd "Institute of Clinical Oncology", Tbilisi, Georgia

A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis

Phase 3

Active, not recruiting

Conditions: Moderately to Severely Active Rheumatoid Arthritis

Interventions: Biological: CT-P13 SC Auto-Injector
Biological: Placebo Auto-Injector

First Posted Date: 2024-12-18

Last Posted Date: 2025-04-25

Lead Sponsor: Celltrion

Target Recruit Count: 192

Registration Number: NCT06738719

Locations: 🇵🇱
Klinika Reuma Park Sp. z.o.o, Warsawa, Poland

To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Biological: CT-P6 SC
Biological: EU-Approved Herceptin SC

First Posted Date: 2024-11-14

Last Posted Date: 2024-11-14

Lead Sponsor: Celltrion

Target Recruit Count: 200

Registration Number: NCT06687928

A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients with Moderate to Severe Psoriasis

Phase 3

Not yet recruiting

Conditions: Plaque Psoriasis

Interventions: Biological: CT-P55
Biological: EU-approved Cosentyx

First Posted Date: 2024-10-08

Last Posted Date: 2024-10-08

Lead Sponsor: Celltrion

Target Recruit Count: 375

Registration Number: NCT06630559

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

Phase 3

Recruiting

Conditions: T2DM

Interventions: Drug: CT-L03 Group 1
Drug: CT-L03 Group 2
Drug: Placebo
Drug: Empagliflozin
Drug: Metformin

First Posted Date: 2024-08-26

Last Posted Date: 2024-08-26

Lead Sponsor: Celltrion

Target Recruit Count: 582

Registration Number: NCT06571591

Locations: 🇰🇷
Celltrion, Incheon, Korea, Republic of

Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Subject

Interventions: Biological: CT-P41
Biological: US-licensed Prolia

First Posted Date: 2023-09-14

Last Posted Date: 2023-09-14

Lead Sponsor: Celltrion

Target Recruit Count: 154

Registration Number: NCT06037395

Locations: 🇰🇷
Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of
🇰🇷
CHA Bundang Medical Center, Seongnam, Bundang-gu, Korea, Republic of

A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers

Phase 1

Completed

Conditions: Essential Hypertension

Interventions: Drug: L04RD1
Drug: L04TD3

First Posted Date: 2023-08-15

Last Posted Date: 2023-08-15

Lead Sponsor: Celltrion

Target Recruit Count: 50

Registration Number: NCT05993806

Locations: 🇰🇷
H plus Yangji Hospital, Seoul, Korea, Republic of

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

Phase 3

Recruiting

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Biological: CT-P53
Biological: US-Ocrevus
Biological: EU-Ocrevus

First Posted Date: 2023-06-18

Last Posted Date: 2024-05-22

Lead Sponsor: Celltrion

Target Recruit Count: 512

Registration Number: NCT05906992

Locations: 🇵🇱
CT-P53 3.1 investigational site, Poznań, Poland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy